Cytokinetics Inc (CYTK)
64.27
+0.90
(+1.42%)
USD |
NASDAQ |
May 02, 14:23
Cytokinetics Cash from Financing (Quarterly): 168.80M for Dec. 31, 2023
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 168.80M |
| September 30, 2023 | 54.22M |
| June 30, 2023 | 5.475M |
| March 31, 2023 | -7.177M |
| December 31, 2022 | 29.88M |
| September 30, 2022 | 389.02M |
| June 30, 2022 | 3.416M |
| March 31, 2022 | 93.85M |
| December 31, 2021 | 19.51M |
| September 30, 2021 | 300.90M |
| June 30, 2021 | 3.175M |
| March 31, 2021 | -3.596M |
| December 31, 2020 | 3.641M |
| September 30, 2020 | 226.33M |
| June 30, 2020 | 4.16M |
| March 31, 2020 | -0.011M |
| December 31, 2019 | 121.12M |
| September 30, 2019 | 11.86M |
| June 30, 2019 | 22.40M |
| March 31, 2019 | 4.416M |
| December 31, 2018 | 0.451M |
| September 30, 2018 | 10.23M |
| June 30, 2018 | 2.978M |
| March 31, 2018 | -0.524M |
| December 31, 2017 | 2.194M |
| Date | Value |
|---|---|
| September 30, 2017 | 1.434M |
| June 30, 2017 | 106.56M |
| March 31, 2017 | 115.73M |
| December 31, 2016 | 0.715M |
| September 30, 2016 | 0.727M |
| June 30, 2016 | 0.589M |
| March 31, 2016 | 14.86M |
| December 31, 2015 | 23.64M |
| September 30, 2015 | 0.164M |
| June 30, 2015 | 0.041M |
| March 31, 2015 | 0.065M |
| December 31, 2014 | 9.134M |
| September 30, 2014 | 0.00 |
| June 30, 2014 | 0.035M |
| March 31, 2014 | 39.78M |
| December 31, 2013 | 7.516M |
| September 30, 2013 | -0.516M |
| June 30, 2013 | 7.483M |
| March 31, 2013 | 0.005M |
| December 31, 2012 | 0.025M |
| September 30, 2012 | -0.412M |
| June 30, 2012 | 56.05M |
| March 31, 2012 | 2.667M |
| December 31, 2011 | 2.394M |
| September 30, 2011 | -0.179M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-7.177M
Minimum
Mar 2023
389.02M
Maximum
Sep 2022
76.16M
Average
19.51M
Median
Dec 2021
Cash from Financing (Quarterly) Benchmarks
| Amgen Inc | 2.754B |
| Johnson & Johnson | 546.00M |
| Eli Lilly and Co | -311.30M |
| Viking Therapeutics Inc | 606.04M |
| Madrigal Pharmaceuticals Inc | 479.92M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -74.04M |
| Cash from Investing (Quarterly) | -81.41M |
| Free Cash Flow | -415.75M |
| Free Cash Flow Per Share (Quarterly) | -0.7479 |
| Free Cash Flow to Equity (Quarterly) | -82.55M |
| Free Cash Flow Yield | -6.70% |